LL-37 peptide claims: separating immune biology from hype

What's this video probably claiming?

Based on the caption and creator context, this video is almost certainly walking through LL-37 as a therapeutic peptide worth using, not just an endogenous immune molecule worth knowing about. The framing, starting with 'your body already makes this,' is a well-worn setup in peptide content: normalize the molecule, then imply that supplementing it makes biological sense. The hashtag 'biofilm' is a tell. LL-37 has documented antibiofilm activity in lab settings, and creators in this space routinely use that data point to suggest LL-37 administration could address chronic infections, Lyme disease complications, or antibiotic-resistant bacterial issues in actual humans. The peptide category tag linking this to BPC-157 and TB-500 suggests the creator is pitching LL-37 as part of a legitimate therapeutic toolkit. That framing deserves scrutiny.

What does the science actually show?

LL-37 is real, well-characterized, and genuinely interesting. It is the sole human cathelicidin, derived from the hCAP18 protein and cleaved to its active form primarily in neutrophils and epithelial cells. Its antimicrobial, antibiofilm, and immunomodulatory functions are documented across hundreds of peer-reviewed studies. Mookherjee et al. (2020, Nature Reviews Drug Discovery) provide a thorough review of cathelicidin biology and acknowledge LL-37 as a plausible drug scaffold. The antibiofilm activity against Pseudomonas aeruginosa and Staphylococcus aureus has been shown in vitro at concentrations of roughly 1-4 micromolar (Overhage et al., 2008, Journal of Bacteriology). However, in vitro activity at controlled concentrations is not clinical efficacy. LL-37 is rapidly degraded by proteases in biological fluids, has short plasma half-life, and its systemic delivery in humans remains almost entirely unvalidated. There are no completed Phase 3 human trials establishing therapeutic dosing for any indication.

Where does the social media noise diverge from clinical reality?

The gap here is significant. Peptide content creators often present in vitro antibiofilm data as though it translates directly to humans clearing chronic infections, which is a serious leap. LL-37 is not an approved therapeutic. It is not available as a regulated pharmaceutical product. Research-grade or compounded LL-37 for injection has no established safety profile in humans at therapeutic doses. There is also a real complication that gets ignored: LL-37 is not uniformly beneficial. Elevated LL-37 expression has been associated with inflammatory skin conditions including rosacea and psoriasis (Lande et al., 2007, Nature), and some cancer biology research has flagged LL-37 as potentially tumor-promoting in certain contexts (Li et al., 2014, Anticancer Research). The 'your body makes it so more is better' logic does not hold. Endogenous peptide biology is tightly regulated for a reason.

What should you actually know?

LL-37 is a legitimate subject of biomedical research, and nobody is disputing the basic immunology. The problem is the translation gap between bench science and clinical use that this style of content consistently papers over. If a creator is implying you should source and administer LL-37, that recommendation has essentially no clinical trial support in humans. The delivery problem alone, rapid protease degradation, poor bioavailability, uncertain dosing windows, makes exogenous LL-37 administration a genuinely unsolved pharmacological challenge. Researchers are actively working on analogues, encapsulation strategies, and topical formulations precisely because native LL-37 does not survive systemic administration well. Anyone presenting this molecule as a usable therapy right now is running well ahead of the evidence. Consult a licensed clinician before approaching any peptide outside of an established clinical protocol.